Awareness of Physicians in Yemen Toward High Blood Pressure Management According to the Eighth Joint National Committee (JNC 8) Guideline

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223. doi:10.1016/S0140-6736(05)17741-1.15652604
   PubMed Web of Science ®Google Scholar
• Lackland DT, Weber MA. Global burden of cardiovascular disease and stroke: hypertension at the core. Can J Cardiol. 2015;31(5):569–571. doi:10.1016/j.cjca.2015.01.009.25795106
   PubMed Web of Science ®Google Scholar
• Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. doi:10.1016/S0140-6736(16)31012-127733281
   PubMed Web of Science ®Google Scholar
• Singh R, Suh I, Singh V, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens. 2000;14(10):749–763. doi:10.1038/sj.jhh.100105711095165
   PubMed Web of Science ®Google Scholar
• Wong TY, Mitchell P. The eye in hypertension. Lancet. 2007;369(9559):425‐435. doi:10.1016/S0140-6736(07)60198-6.
   Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.24352797
   PubMed Web of Science ®Google Scholar
• Chobanian AV. National heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee: the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–2572. doi:10.1001/jama.289.19.256012748199
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62(16):1495–1539. doi:10.1016/j.jacc.2013.05.020
   Web of Science ®Google Scholar
• Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25Part B):2960–2984. doi:10.1016/j.jacc.2013.11.00324239922
   PubMed Web of Science ®Google Scholar
• ACOG. ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26–e50.30575676
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):1376–1414. doi:10.1016/j.jacc.2019.03.00930894319
   PubMed Web of Science ®Google Scholar
• Hill MN, Miller NH, Degeest S, et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011;5(1):56–63. doi:10.1016/j.jash.2011.01.00121320699
   PubMed Web of Science ®Google Scholar
• Ardery G, Carter BL, Milchak JL, et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens (Greenwich). 2007;9(2):113–119. doi:10.1111/j.1524-6175.2007.06112.x17268216
   PubMedGoogle Scholar
• Motlagh B, O’Donnell M, Yusuf S. Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16(3):268–280. doi:10.1097/HJR.0b013e328322ca1b.19398913
   PubMedGoogle Scholar
• Al-Shaer MY, Bamashmus MA, Al-Akily SA, Al-Akhlee HA. Prevalence of hypertension, diabetes mellitus and Hepatitis B and C among people seeking cataract surgery in eye camps in Yemen. Yemeni J Med Health Res. 2019;8:1&2.
   Google Scholar
• MOPHP. Annual Statistical Health Report. mophp website 2014. Available from: http://www.mophp-ye.org/arabic/docs/Report2011.pdf. Accessed 31, 2019..
   Google Scholar
• Al-Azzam SI, Najjar RB, Khader YS. Awareness of physicians in Jordan about the treatment of high blood pressure according to the seventh report of the Joint National Committee (JNC VII). Eur J Cardiovasc Nurs. 2007;6(3):223–232. doi:10.1016/J.EJCNURSE.2006.10.001.17142103
   PubMedGoogle Scholar
• Al-Gelban KS, Khan MY, Al-Khaldi YM, et al. Adherence of primary health care physicians to hypertension management guidelines in the Aseer region of Saudi Arabia. Saudi J Kidney Dis Transpl. 2011;22(5):941‐948.
   Google Scholar
• Alshehri NA, Almigbal TH, Alodhayani A, Batais MA. Family and internal medicine resident’s awareness of and adherence to the Joint National Committee 8 (JNC 8) hypertension guidelines: a cross sectional study. Biomed Res. 2017;28:12.
   Google Scholar
• Haller H, Ito S, JL I Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–917. doi:10.1056/NEJMoa100799421388309
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19). e127–e248.29146535
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329(7470):828. doi:10.1136/bmj.38237.585000.7C.15459003
   PubMed Web of Science ®Google Scholar
• Contreras G, Greene T, Agodoa LY, et al. Blood pressure control, drug therapy, and kidney disease. Hypertension. 2005;46(1):44–50. doi:10.1161/01.HYP.0000166746.04472.6015897360
   PubMed Web of Science ®Google Scholar
• Silvariño R, Rios P, Baldovinos G, et al. Is chronic kidney disease progression influenced by the type of renin-angiotensin-system blocker used? Nephron. 2019;143(2):100–107. doi:10.1159/00050092531203280
   PubMed Web of Science ®Google Scholar
• Zheng CM, Wang JY, Chen TT, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. Sci Rep. 2019;9(1):2694. doi:10.1038/s41598-019-38991-z30804406
   PubMed Web of Science ®Google Scholar
• DeJong C, Grant RW. Continuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the face of kidney disease progression-safe and possibly life saving. JAMA Intern Med. 2020;180(5):727. doi:10.1001/jamainternmed.2020.0300.
   Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N;for Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356(9246):1955–1964. doi:10.1016/s0140-6736(00)03307-9.11130523
   PubMed Web of Science ®Google Scholar
• Harrow C, Fisher M. Strokes and diabetes. Pract Diabetes Int. 2005;22(6):215–221. doi:10.1002/pdi.820.
   Google Scholar
• Tzourio C, Anderson C, Chapman N, et al. for PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069–1075.12742805
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392. doi:10.1056/NEJMoa131373124716680
   PubMed Web of Science ®Google Scholar
• Edelmann F, Musial-Bright L, Gelbrich G, et al. Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: insights from the CIBIS-ELD trial. JACC Heart Fail. 2016;4(2):140–149. doi:10.1016/j.jchf.2015.10.00826682793
   PubMed Web of Science ®Google Scholar
• Al-Ali KA, Al-Ghanim FA, Al-Furaih AM, Al-Otaibi N, Makboul G, El-Shazly MK. Awareness of hypertension guidelines among family physicians in primary health care. Alexandria J Med. 2013;49(1):81–87. doi:10.1016/j.ajme.2012.07.003.
   Google Scholar
• Himmelmann A. New information on the role of beta-blockers in cardiac therapy. Cardiovasc Drugs Ther. 1999;13(6):469–477. doi:10.1023/A:1007893301243.10686655
   PubMed Web of Science ®Google Scholar
• Khan NA, McAlister FA, Rabkin SW, et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - Therapy. Can J Cardiol. 2006;22(7):583‐593. doi:10.1016/S0828-282X(06)70280-X
   Web of Science ®Google Scholar
• Raio L, Bolla D, Baumann M. Hypertension in pregnancy. Curr Opin Cardiol. 2015;30(4):411–415. doi:10.1097/HCO.0000000000000190.26049391
   PubMed Web of Science ®Google Scholar
• Battarbee AN, Sinkey RG, Harper LM, Oparil S, Tita ATN. Chronic hypertension in pregnancy. Am J Obstet Gynecol. 2020;222(6):532–541. doi:10.1016/j.ajog.2019.11.1243.31715148
   PubMed Web of Science ®Google Scholar
• Shah S. Hypertensive Disorders in Pregnancy. Obstetric and Gynecologic Nephrology. Springer; 2020:11–23.
   Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-116154016
   PubMed Web of Science ®Google Scholar